Saturday 17 October 2026
Export FEMY’s income statement to Excel — free account
Femasys Inc.
FEMY Healthcare Medical Instruments & Supplies
Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024. In the quarter to June 2026, revenue fell 18.9%, EPS grew 58.4%, free cash flow grew 11.3% and total debt rose 3,369.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.65
0.09
−5.17%
Follow FEMY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.10 | 11.78 | 9.93 | 7.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.57) | (6.76) | (5.44) | (2.68) | |
P/B ratio |
3.48 | 3.84 | 3.88 | 3.17 | |
Price to Tangible BV |
3.58 | 3.91 | 3.97 | 3.26 | |
EV/Sales |
7.05 | 11.16 | 8.20 | 4.84 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.92) | (1.47) | (1.01) | (0.51) | |
EV/FCF |
(0.90) | (1.43) | (0.98) | (0.50) | |
Quick Ratio |
0.41 | 1.76 | 2.72 | 0.49 | |
Current Ratio |
2.14 | 3.91 | 4.53 | 1.16 | |
Net Debt/EBITDA |
(0.45) | 0.37 | 0.87 | 1.03 | |
Debt/Assets |
29.44% | 23.83% | 25.56% | 0.64% | |
Debt/Equity |
0.90 | 0.54 | 0.90 | 0.02 | |
Asset Turnover |
0.18 | 0.16 | 0.14 | 0.13 | |
Operating CF/Net income |
0.88 | (12.61) | 1.06 | 1.28 | |
Capex/Depreciation |
(0.03) | (0.31) | (1.64) | 0.29 | |
Interest Coverage |
(27.22) | (23.92) | (11.33) | (6.87) | |
Research and Development Expense of Revenue |
586.77% | 308.17% | 222.87% | 189.47% | |
Selling, General and Administrative Expense of Revenue |
972.15% | 729.14% | 397.71% | 359.42% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
63.53% | 35.68% | 8.16% | 23.92% | |
Graham Net Nets |
0.01 | 0.11 | 0.07 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(84.45%) | (64.29%) | (86.81%) | (204.55%) | |
Free Cash Flow Yield |
(128.81%) | (66.36%) | (84.35%) | (139.02%) | |
Revenue per Share |
0.10 | 0.13 | 0.41 | 0.36 | |
Operating CF per Share |
(1.17) | (1.24) | (2.12) | (2.63) | |
Capex per Share |
0.00 | (0.02) | (0.07) | (0.09) | |
Free Cash Flow per Share |
(1.18) | (1.27) | (2.19) | (2.72) | |
Cash per Share |
0.43 | 1.62 | 4.69 | 2.23 | |
Shareholders Equity per Share |
1.20 | 2.19 | 2.97 | 2.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.20 | 2.19 | 2.97 | 2.22 | |
Free Cash Flow |
(3.95) | (4.22) | (4.33) | (5.58) | |
Working Capital |
4.45 | 9.19 | 12.82 | 1.71 | |
Capital Expenditures |
(0.01) | (0.08) | (0.14) | (0.19) | |
Net Current Asset Value |
0.07 | 3.14 | 1.60 | 0.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.19 | 0.17 | 0.27 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.20 | 0.20 | 0.55 | 0.48 | |
Average Payables |
2.80 | 1.96 | 1.62 | 1.65 | |
Average Inventory |
5.71 | 4.98 | 4.39 | 3.86 | |
Average Assets |
13.04 | 14.89 | 16.58 | 15.94 | |
Average Common Equity |
2.77 | 4.64 | 4.09 | 5.26 |
Columns are period end dates